Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Upper Respiratory Drugs: First and Second-Generation Antihistamines

Upper Respiratory Drugs: First and Second-Generation Antihistamines

Antihistamines are a class of drugs widely used to alleviate the symptoms of allergies, such as sneezing, itching, and nasal congestion. They work by inhibiting the actions of histamine, which is released by immune cells in response to allergenic substances or tissue injuries.
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

Prescription, Nonprescription and Orphan Drugs

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...

Drug Biotransformation: Overview

Drug Biotransformation: Overview

Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...

Drug Biotransformation: Overview

Drug Biotransformation: Overview

Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Microglandular adenosis, triple negative breast carcinoma and DNA repair defects.

Journal of clinical pathology·2026

Same author

Patient, family caregiver, and economic outcomes of an integrated screening and novel stepped collaborative care intervention in the oncology setting in the USA (CARES): a randomised, parallel, phase 3 trial.

Lancet (London, England)·2024

Same author

Topical Cannabinoids for Treating Chemotherapy-Induced Neuropathy: A Case Series.

Integrative cancer therapies·2021

Same author

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.

JAMA oncology·2021

Same author

Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma.

Bone marrow transplantation·2018

Same author

Hepatotoxicity Associated With Vismodegib.

BMJ case reports·2018

Search research articles

Related Experiment Video

Updated: Jun 14, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Bendamustine: something old, something new.

Nishant Tageja¹, Jasdeepa Nagi

¹Department of Internal Medicine, Detroit Medical Center, Wayne State University, Detroit, MI, USA. ntageja@med.wayne.edu

Cancer Chemotherapy and Pharmacology

|April 9, 2010

Summary

Bendamustine combined with rituximab shows high efficacy in treating indolent lymphomas, with over 90% remission rates in relapsed-refractory patients. This combination is a promising new treatment option for follicular lymphoma and mantle cell lymphoma.

Related Experiment Videos

Last Updated: Jun 14, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Area of Science:

Oncology
Hematology
Pharmacology

Background:

Bendamustine is a bifunctional chemotherapeutic agent with antimetabolite properties and limited cross-resistance with other alkylators.
Its unique mechanism and favorable side-effect profile suggest a significant role in managing lymphoproliferative disorders.
Bendamustine is an orphan drug in the US, ensuring market exclusivity.

Purpose of the Study:

To comprehensively review data on the efficacy and toxicity of bendamustine in treating lymphoproliferative neoplasms.
To review bendamustine's pharmacology, pharmacokinetics, and pre-clinical studies.
To evaluate bendamustine's role in combination therapy for indolent lymphomas.

Main Methods:

Searched MEDLINE and Pubmed databases (1970-2010) using terms: bendamustine, Treanda, Ribomustin, etc.
Reviewed relevant articles and screened references for additional studies.
Searched American Society of Hematology (2004-2009) and American Society of Clinical Oncology (1995-2009) databases for abstracts.

Main Results:

Bendamustine induces remission in over 75% of rituximab-refractory indolent B-cell non-Hodgkin lymphoma (NHL) patients.
Bendamustine plus rituximab demonstrates synergistic effects against leukemia and lymphoma cell lines in vitro.
Clinical trials show bendamustine plus rituximab achieves over 90% remission and 23-24 months median progression-free survival in relapsed-refractory indolent lymphoma.

Conclusions:

The combination of bendamustine and rituximab shows potential as a new first-line treatment for follicular lymphoma (FL), mantle cell lymphoma (MCL), and indolent lymphomas.
Ongoing trials will further define bendamustine's optimal role in indolent NHL.
Bendamustine is well-tolerated with a low propensity for alopecia.